

CDR based peptides- list of publications

1. A. Waisman, P.J. Ruiz, E. Israeli, E. Eilat, S. Könen-Waisman, H. Zinger, M. Dayan and E. Mozes. Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of a pathogenic anti-DNA monoclonal antibody. *Proc. Natl. Acad. Sci. USA* **94**, 4620-4625 (1997).
2. E. Mozes. Experimental systemic lupus erythematosus: From a pathogenic autoantibody to immunomodulating peptides. In: *The Decade of Autoimmunity*. (Y. Shoenfeld, ed.) Elsevier Science Publications, Amsterdam p.109-117 (1999).
3. N. Brosh, E. Eilat, H. Zinger and E. Mozes. Characterization and role in experimental systemic lupus erythematosus of T-cell lines specific to peptides based on complementarity-determining region-1 and complementarity-determining region 3 of a pathogenic anti-DNA monoclonal antibody. *Immunology* **99**, 257-265 (2000).
4. N. Brosh, M. Dayan, M. Fridkin and E. Mozes. A peptide based on the CDR3 of an anti-DNA antibody of experimental SLE origin is also a dominant T-cell epitope in (NZBxNZW)F1 lupus-prone mice. *Immunol. Letters* **72**, 61-68 (2000).
5. M. Dayan, R. Segal, Z. Stoege, A. Waisman, N. Brosh, O. Elkayam, E. Eilat, M. Fridkin and E. Mozes. Immune response of SLE patients to peptides based on the complementarity determining regions of a pathogenic anti-DNA monoclonal antibody. *J. Clin. Immunol.* **20**, 187-194 (2000).
6. E. Eilat, H. Zinger, A. Nyska and E. Mozes. Prevention of systemic lupus erythematosus-like disease in (NZBxNZW)F1 mice by treating with CDR1-and CDR3-based peptides of a pathogenic autoantibody *J. Clin. Immunol.* **20**,268-278 (2000).
7. N. Brosh, H. Zinger, M. Fridkin and E. Mozes. A peptide based on the sequence of the CDR3 of a murine anti-DNA mAb is a better modulator of experimental SLE than its single amino acid-substituted analogs. *Cell. Immunol.* **205**, 52-61 (2002).
8. E. Eilat, M. Fridkin and E. Mozes. A peptide based on the CDR1 of a pathogenic anti-DNA antibody is more efficient than its analogs in inhibiting autoreactive T cells. *Immunobiol.* **202**, 383-393 (2000).
9. E. Eilat, M. Dayan, H. Zinger and E. Mozes. The mechanism by which a peptide based on complementarity-determining region-1 of a pathogenic anti-DNA auto-Ab ameliorates experimental systemic lupus erythematosus. *Proc. Natl. Acad. Sci. USA.* **98**, 1148-1153 (2001).
10. N. Brosh, H. Zinger and E. Mozes. Treatment of induced murine SLE with a peptide based on the CDR3 of an anti-DNA antibody reverses the pattern of pathogenic cytokines. *Autoimmunity.* **35**, 211-219 (2002).
11. A. Faber-Elmann, E. Eilat, H. Zinger and E. Mozes. A peptide based on an anti-DNA autoantibody downregulates matrix metalloproteinases in murine models of lupus. *Clin. Immunol.* **105**, 223-232 (2002).
12. H. Zinger, E. Eilat, A. Meshorer and E. Mozes. Peptides based on the complementarity-determining regions of a pathogenic autoantibody mitigate lupus manifestations of (NZBxNZW)F1 mice via active suppression. *International Immunol.* **15**, 205-214 (2003).
13. Z.M. Stoege, M. Dayan, A. Tcherniack, L. Green, S. Toledo, R. Segal, O. Elkayam and E. Mozes. Modulation of autoreactive responses of peripheral blood lymphocytes of patients with systemic lupus erythematosus by peptides based on

- human and murine anti-DNA autoantibodies. *Clin. Exp. Immunol.* **131**, 385-392 (2003).
14. D. Luger, M. Dayan, H. Zinger, J.-P. Liu and E. Mozes. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation. *J. Clin. Immunol.* **24**, 579-590 (2004).
 15. N. Mauermann, Z. Sthoeger, H. Zinger and E. Mozes. Amelioration of lupus manifestations by a peptide based on the complementarity determining region 1 of an autoantibody in severe combined immunodeficient (SCID) mice engrafted with peripheral blood lymphocytes of systemic lupus erythematosus (SLE) patients. *Clin. Exp. Immunol.* **137**, 513-520 (2004).
 16. U. Sela, R. HersHKoviz, L. Cahalon, O. Lider and E. Mozes. Down-regulation of stromal cell-derived factor-1 α -induced T cell chemotaxis by a peptide based on the complementarity-determining region 1 of an anti-DNA autoantibody via up-regulation of TGF- β secretion. *J. Immunol.* **174**, 302-309 (2005).
 17. U. Sela, N. Mauermann, R. HersHKoviz, H. Zinger, M. Dayan, L. Cahalon, J.-P. Liu, E. Mozes and O. Lider. The inhibition of autoreactive T cell functions by a peptide based on the CDR1 of an anti-DNA autoantibody is via TGF- β mediated suppression of LFA-1 and CD44 expression and function. *J. Immunol.* **175**, 7255-7263 (2005).
 18. M.J. Rapoport, A. Sharabi, D. Aharoni, O. Bloch, H. Zinger, M. Dayan and E. Mozes. Amelioration of SLE-like manifestations in (NZBxNZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a down-regulation of apoptosis and of the pro-apoptotic factor JNK kinase. *Clin. Immunol.* **117**, 262-270 (2005).
 19. A. Sharabi, A. Haviv, H. Zinger, M. Dayan and E. Mozes. Amelioration of murine lupus by a peptide, based on the complementarity determining region-1 of an autoantibody as compared to dexamethasone: Different effects on cytokines and apoptosis. *Clin. Immunol.* **119**, 146-155 (2006).
 20. U. Sela, M. Dayan, R. HersHKoviz, L. Cahalon, O. Lider and E. Mozes. The negative regulators Foxj1 and Foxo3 α are up-regulated by a peptide that inhibits systemic lupus erythematosus-associated T cell responses. *Eur. J. Immunol.* **36**, 2971-2980 (2006).
 21. A. Sharabi, H. Zinger, M. Zborowsky, Z.M. Sthoeger and E. Mozes. A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4⁺CD25⁺ cells and TGF- β . *Proc. Natl. Acad. Sci. USA* **103**, 8810-8815 (2006).
 22. A. Elmann, A. Sharabi, M. Dayan, H. Zinger, R. Ophir and E. Mozes. Altered gene expression in mice with lupus treated with Edratide, a peptide that ameliorates the disease manifestations. *Arthritis Rheum.* **56**, 2371-2381 (2007).
 23. A. Sharabi, H. Azulai, Z.M. Sthoeger and E. Mozes. Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: similarities and differences in the mechanisms of action. *Immunology* **121**, 248-257 (2007).
 24. A. Sharabi, D. Luger, H. Ben-David, M. Dayan, H. Zinger and E. Mozes. The role of apoptosis in the ameliorating effects of a CDR1-based peptide on lupus manifestations in a mouse model. *J. Immunol.* **179**, 4979-4987 (2007).
 25. E. Mozes, U. Sela, A. Sharabi. A novel synthetic peptide for the specific treatment of lupus: Clinical effects and mechanisms of action. *IMAJ* **10**, 40-42 (2008).

26. Sela U, Dayan M, Hershkovich R, Lider O, Mozes E. A Peptide that ameliorates lupus up-regulates the diminished expression of early growth response factors 2 and 3. *J Immunol.* **180**, 1584-91 (2008).
27. A. Sharabi, E. Mozes. The suppression of murine lupus by a tolerogenic peptide involves Foxp3-expressing CD8 cells that are required for the optimal induction and function of Foxp3-expressing CD4 cells. *J Immunol.* **181**,3243-51 (2008).
28. U. Sela, A. Sharabi, M. Dayan, R. Hershkovich, E. Mozes. The role of dendritic cells in the mechanism of action of a peptide that ameliorates lupus in murine models. *Immunology*, **128**,e395-e405 (2008).
29. Z.M. Sthoeger, A. Sharabi, M. Dayan H. Zinger, I. Asher, U. Sela, E. Mozes. The tolerogenic peptide, hCDR1, down-regulates pathogenic cytokines and apoptosis and up-regulates immunosuppressive molecules and regulatory T cells in peripheral blood mononuclear cells of lupus patients. *Human Immunol.* **70**,139-45 (2009).
30. R. Parameswaran, H. Ben David, A. Sharabi, H. Zinger, E. Mozes. B-cell activating factor (BAFF) plays a role in the mechanism of action of a tolerogenic peptide that ameliorates lupus. *Clin. Immunol.* **131**, 223-32 (2009).
31. Z.M. Sthoeger, A. Sharabi, Y. Molad, I. Asher, H. Zinger, M. Dayan, E. Mozes. Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): Immunomodulation of gene expression. *J. Autoimmunity*, **33**, 77-82 (2009).
32. A. Sharabi, E. Mozes. Harnessing regulatory T cells for the therapy of lupus and other autoimmune diseases. Review, *Immunotherapy*, 1, 385-401 (2009).
33. H. Ben-David, A Sharabi, R. Parameswaran, H. Zinger, E. Mozes. A tolerogenic peptide down-regulates mature B cells in bone marrow of lupus-afflicted mice by inhibition of IL-7, leading to apoptosis. *Immunology.* **128**, 245-252 (2009).
34. A. Sharabi, S. Lapter, E. Mozes. Bcl-xL is required for the development of functional regulatory CD4 cells in lupus-afflicted mice following treatment with a tolerogenic peptide. *J. Autoimmunity.* **34**, 87-95 (2010).
35. A. Sharabi, Z.M. Sthoeger, K. Mahlab, S. Lapter, H. Zinger, E. Mozes. A tolerogenic peptide that induces suppressor of cytokine signaling (SOCS)-1 restores the aberrant control of IFN- γ signaling in lupus-inflicted (NZBxNZW)F1 mice. *Clin. Immunol.* **133**, 61-68 (2009).
36. S. Lapter, A. Marom, A. Meshorer, A. Elmann, A. Sharabi, E. Vadai, A. Neufeld, Y. Sztainberg, S. Gil, D. Getselter, A. Chen, E. Mozes. Amelioration of brain pathology and behavioral dysfunction of mice with systemic lupus erythematosus following treatment with a tolerogenic peptide. *Arthritis Rheum.* **60**, 3744-3754 (2009).
37. A. Arazi, A. Sharabi, H. Zinger, E. Mozes, A.U.Neumann. In vivo dynamical interactions between CD4 Trgs, CD8 Tregs and CD4⁺CD25⁻ cells in mice. *PLoS ONE.* **4**, (issue 12) e8447 (2009).
38. A. Sharabi, M. Dayan, H. Zinger, E. Mozes. A new model of induced experimental systemic lupus erythematosus (SLE) in pigs and its amelioration by treatment with a tolerogenic peptide. *J. Clin. Immunol.* **30**, 34-44 (2010).
39. A. Sharabi, E. Mozes. Bcl-xL affects the development of functional CD4 Tregs. *Arthritis research & Therapy.* **12**, 405 (2010).
40. S. Lapter, H. Ben-David, A Sharabi, H. Zinger, A. Telerman, M. Gordin, L. Leng, R. Bucala, I. Shachar, E. Mozes. A role for the B cell CD74/MIF pathway in the immunomodulation of systemic lupus erythematosus by a therapeutic tolerogenic peptide. *Immunology.* **132**,87-95(2011).
[doi:10.1111/j.1365-2567.2010.03342.x(2010)].

41. E. Mozes, A. Sharabi. A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosus. *Autoimmunity Reviews*. 10, 22-26 (2010).
42. A. Telerman, S. Lapter, A. Sharabi, H. Zinger, E. Mozes. Induction of hippocampal neurogenesis by a tolerogenic peptide that ameliorates lupus manifestations. *J. Neuroimmunol.* 232, 151-157 (2011).
43. Z. Stoeber, H. Zinger, A. Sharabi, I. Asher, E. Mozes. The tolerogenic peptide, hCDR1, down-regulates the expression of interferon- α in murine and human systemic lupus erythematosus. *PLoS One*. 8 (issue 3), e60394 (2013).